Sustained-release injectables formed in situ and their potential use for veterinary products

Journal of Controlled Release

Volumn 85, Issue 1-3, 2002, Pages 1-15

  Matschke, Christian ^a,d   Isele, Ute ^a   Van Hoogevest, Peter ^b   Fahr, Alfred ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Phares Drug Delivery AG   (Switzerland)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d ALTANA PHARMA AG   (Germany)

Author keywords

Controlled release; Implant; In situ; Injectable; Sustained; Veterinary

Indexed keywords

COPOLYMER; GLYCEROL OLEATE; IVERMECTIN; MACROGOL; MIGLYOL; POLOXAMER; POLYACRYLIC ACID; POLYMER; POLYMETHACRYLIC ACID; POLYSORBATE 80; RESOMER; SORBITAN OLEATE; SUCROSE ACETATE ISOBUTYRATE; VETERINARY DRUG;

BIODEGRADATION; MOLECULAR BIOLOGY; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SUSTAINED RELEASE PREPARATION; VETERINARY MEDICINE; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; POLYMERS; VETERINARY DRUGS;

EID: 0037073658     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00266-3     Document Type: Review

References (131)

1. Cardinal R. Controlled drug delivery: veterinary applications. J. Controlled Release. 2:1985;393-403.
2. Arnold R.G. Controlled-release new animal drugs. J. Controlled Release. 8:1988;85-90.
3. Carter D.H., Luttinger M., Gardner D.L. Controlled release parenteral systems for veterinary applications. J. Controlled Release. 8:1988;15-22.
4. Rathbone M.J., Mcmillan K.L., Inskeep K., Burggraaf S., Bunt C.R. Fertility regulation in cattle. J. Controlled Release. 54:1998;117-148.
5. Rothen-Weinhold A., Dahn M., Gurny R. Formulations and technology aspects of controlled drug delivery in animals. Pharm. Sci. Technol. Today. 3:2000;222-231.
6. L.C. Withey-Lakshmann, Y. Li, Controlled drug delivery and the companion animal, in: M.J. Rathbone, R. Gurny (Eds.), Controlled Release Veterinary Drug Delivery, Elsevier Science, Amsterdam, 2000, pp. 249-268.
7. Simmons J., Hammer C. Inhibition of estrous in the dog with testosterone implants. Am. J. Vet. Res. 70:1973;249-250.
8. Okada H., Inoue Y., Heya T., Ueno H., Ogawa Y., Togushi H. Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate. Pharm. Res. 8:(6):1991;791-797.
9. Bahk J.Y., Hyun J.S., Lee J.Y., Kim J., Cho Y.H., Lee J.H., Park J.S., Kim M.O. Concentration of ofloxacin in canine tissue and prostate: fluid after intraprostatic injection of biodegradable sustained-releasing microspheres. J. Urol. 163:(5):2000;1560-1564.
10. Gupta P.K., Johnson H., Allexon C. In vitro and in vivo evaluation of clarithromycin PLA microspheres for intramuscular drug delivery. J. Controlled Release. 26:(3):1993;229-238.
11. Shih C., Fix J., Stewart R.L. In vitro and in vivo release of ivermectin from poly(orthoester) matrices I. Crosslinked matrix prepared from ketene acetal end-capped prepolymer. J. Controlled Release. 25:1993;155-162.
12. Dunn R.L., Yewey G.L., Fujita S.M., Whitman S.L., Southard G.L., Dernell W.S., Straw R.C., Withrow S.J., Powers B.E. Sustained release of cisplatin in dogs from an injectable delivery system. J. Bioact. Compat. Polym. 11:(4):1996;286-300.
13. R.L. Dunn, J.P. English, D.R. Cowsar, D.P. Vanderbilt, Biodegradable in situ forming implants and methods of producing the same, US patent No. 5,278,201, January 11, 1994.
14. Rock D., Heaney K., Peterson D., Barton W., Levy S., Smith L., Terhune T. Field evaluation of a moxidectin sustained release injectable for the prevention of heartworm disease in dogs. Proc. Am. Assoc. Vet. Parasitol. 45:2000;56.
15. Paul A.J., Hutchens D.E., Cleale R.M., Tranquilli W. Clinical observation from the administration of moxidectin canine sustained release injectable in ivermectin sensitive dogs. Proc. Am. Assoc. Vet. Parasitol. 45:2000;56.
16. Butler J.M., Vaughan J.L., Rulli R.D. Clinical observations following the administration of moxidectin canine sustained release (SR) injectable in heartworm positive dogs. Proc. Am. Assoc. Vet. Parasitol. 45:2000;57.
17. McCall J., Lok J., Knight D., Dzimianski M., Cleale R., Steber W., Doscher M., Heaney K. Six-month prophylactic efficacy of a sustained release 10% moxidectin injectable against Dirofilaria immiti. Proc. Am. Assoc. Vet. Parasitol. 45:2000;58.
18. Tice T.R., Tabibi E.S. Parenteral drug delivery: injectables. Kydonieus A. Treatise on Controlled Drug Delivery: Fundamentals, Optimization, Application. 1991;315-339 Marcel Decker, New York.
19. Conti B., Pavanetto F., Genta I. Use of polylactic acid for the preparation of microparticulate drug delivery system. J. Microencapsul. 9:1992;153-166.
20. Thomasin C., Merkle H.P., Gander B.A. Physico-chemical parameters governing protein microencapsulation into biodegradable polyester by coacervation. Int. J. Pharm. 147:1997;173-186.
21. Nihant N., Grandfils C., Jérôme R., Teyssié P. Microencapsulation by coacervation of poly(lactide-co-glycolide) IV: Effect of processing parameters and encapsulation. J. Controlled Release. 35:1995;117-125.
22. Jali R., Nixon J.R. Biodegradable poly(lactic) acid and poly (lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties. J. Microencapsul. 7:1990;297-325.
23. Arshady R. Microspheres and microcapsules: a survey of manufacturing techniques. Part II: Coacervation. Polym. Eng. Sci. 30:1990;905.
24. Arshady R. Microspheres and microcapsules: a survey of manufacturing techniques, Part III. Polym. Eng. Sci. 30:1990;915.
25. Nihant N., Schugens C., Grandfils C., Jérôme R., Teyssié P. Polylactide microparticles prepared by double emulsion/evaporation technique. Pharm. Res. 11:1994;1479-1484.
26. Shah H.K., Toddywala R., Chien Y.W. Biodegradable microcapsules prepared by a w/o/w technique: effects of shear force to make a primary w/o emulsion on their morphology and protein release. J. Microencapsul. 12:1995;59-69.
27. Gander B.A., Wehrli E., Adler R., Merkle H.P. Quality improvement of spray dried, protein loaded D,L-PLA microspheres by appropriate polymer solvent selection. J. Microencapsul. 12:1995;83-97.
28. Wagenaar B.W., Müller B.W. Piroxicam release from spray-dried biodegradable microspheres. Biomaterials. 15:(1):1994;49-54.
29. Jameela S.R., Suma N., Jayakrishnan A. Protein release from poly(e-caprolactone) microspheres prepared by melt encapsulation and solvent evaporation technique: a comparative study. J. Biomater. Sci. Polym. Ed. 8:(6):1997;457-466.
30. Franssen O., Hennink W.E. A novel preparation method for polymeric microparticles without the use of organic solvents. Int. J. Pharm. 168:1998;1-7.
31. Macadam A.B., Shafi Z.B., James S.L., Marriott C., Martin G.P. Preparation of hydrophobic and hydrophilic albumin microspheres and determination of surface carboxylic acid and amino residues. Int. J. Pharm. 151:(1):1997;47-55.
32. Fujioka K., Takada Y., Sato S., Miyata T. Novel delivery system for proteins using collagen as a carrier material: the minipellet. J. Controlled Release. 33:1995;307-315.
33. Tabata Y., Ikada Y. Protein release from gelatine matrices. Adv. Drug Deliv. Rev. 31:(3):1998;287-301.
34. Gombotz W.R., Wee S.F. Protein release from alginate matrices. Adv. Drug Deliv. Rev. 31:(3):1998;267-285.
35. Ka H.S. Chitosan: properties, preparations and application to microparticulate systems. J. Microencapsul. 14:1997;689-711.
36. Leong K.W., Kost J., Mathiowitz E., Langer R. Polyanhydrides for controlled release of bioactive agents. Biomaterials. 7:1986;364-371.
37. Heller J., Barr J., Ng S.Y., Shen H.R., Schwach-Abdellaoui K., Emmahl S., Rothen-Weinhold A., Gurny R. Poly(ortho esters) - their development and some applications. Eur. J. Pharm. Biopharm. 50:2000;121-128.
38. Uhlrich K.E., Cannizzaro S.M., Langer R.S. Polymeric systems for controlled drug release. Chem. Rev. 99:1999;3181-3198.
39. Wang N., Wu X.S., Li C., Feng M.F. Synthesis, characterisation, biodegradation and drug delivery application of biodegradable lactic/glycolic polymers: synthesis and characterisation. J. Biomater. Sci. Polym. Ed. 11:(3):2000;301-318.
40. Wu X.S. Synthesis and properties of biodegradable lactic/glycolic acid polymers. Wise D.L., Trantolo D.J., Altobelli D.E., Yaszemski M.J., Gresser J.D., Schwarz E.R. Part A: Materials. Encyclopedic Handbook of Biomaterials and Bioengineering. 1995;1015-1054 Marcel Decker, New York.
41. Tice T.R., Crossar D.R. Biodegradable controlled-release parenteral systems. Pharm. Technol. 11:1984;26-35.
42. Lewis D.H. Controlled release of bioactive agents form lactide/glycolide polymers. Chasin M., Langer R. Biodegradable Polymers as Drug Delivery Systems. 1990;1-41 Marcel Decker, New York.
43. Göpferich A. Polymer degradation and erosion: mechanisms and applications. Eur. J. Pharm. Biopharm. 42:(1):1996;1-11.
44. Li S.M., Garreua H., Vert M. Structure property relationship in the case of the degradation of massive poly(hydroxy) acids in aqueous media. Part 3. Influence of the morphology of poly(L-lactic acid). J. Mater. Sci. Mater. Med. 1:1990;198-206.
45. Pistner H., Bendix D.R., Mühlig J., Reuter J.F. Poly(L-lactide): a long-term degradation study in vivo. Biomaterials. 4:1993;291-298.
46. Radomsky M.L., Brouwer G., Floy B.J., Loury D.J., Chu F., Tipton A.J., Sanders L.M. The controlled release of Generalix from the Atrigel injectable implant system. Proc. Int. Symp. Control. Rel. Bioact. Mater. 20:1993;458-459.
47. Shah H., Railkar A.S., Chen F.C., Tarantino R., Kumar S., Murjani M., Palmer D., Infeld M.H., Malick A.W. A biodegradable implant for delivering micro and macromolecules using poly(lactic-co-glycolic) acid (PLGA) copolymers. J. Controlled Release. 27:1993;139-147.
48. Sweetana S., Akers M.J. Solubility principles and practices for parenteral drug dosage form development. J. Parenter. Sci. Technol. 50:(5):1996;330-342.
49. Wang Y.J., Kowal R.R. Review of excipients and pH's for parenteral products used in the United States. J. Parenter. Drug Assoc. 34:1990;452-462.
50. Mottu F., Laurent A., Rüfenacht D.A., Doelker E. Organic solvents for pharmaceutical parenterals and embolic liquids: a review of toxicity data. J. Parenter. Sci. Technol. 54:(6):2000;457-469.
51. Bleiberg B., Beers T.R., Persson M., Miles J. Metabolism of triacetin-derived acetate in dogs. Am. J. Clin. Nutr. 58:1993;908-911.
52. Graham D., Brodbeck K.J., McHugh A.J. Phase inversion dynamics of PLGA solutions related to drug delivery. J. Controlled Release. 58:1999;233-245.
53. Eliaz R.E., Kost J. Characterization of a polymeric PLGA-injectable implant delivery system for the controlled release of proteins. J. Biomed. Mater. Res. 50:(3):2000;388-396.
54. R.T. Chern, J.R. Zingermann, Liquid polymeric compositions for controlled release of bioactive substances, WO publication No. 9947073, September 23, 1999.
55. Lifschitz A., Pis A., Alvarez L., Sanchez G., Sallovitz J., Kujanek R., Lanusse C. Bioequivalence of ivermectin formulations in pigs and cattle. J. Vet. Pharmacol. Therap. 22:(1):1999;27-34.
56. McManus E.C., Pulliam J.D. Histopathologic features of canine heartworm microfilarial infection after treatment with ivermectin. Am. Vet. Res. 45:(1):1984;91-97.
57. ICH Topic Q3C (M) Maintenance of Note For Guidance on Impurities: Residual Solvents (CPMP, ICH/283/95). 2000;The European Agency for the Evaluation of Medical Products, London.
58. Royals M.A., Fujita S.M., Yewey G.L., Rodriguez J., Schultheiss P.C., Dunn R.L. Biocompatibility of a biodegradable in-situ forming implant system in rhesus monkeys. J. Biomed. Mater. Res. 45:(3):1999;231-239.
59. Shivley M.L., Coonts B.A., Renner W.D., Southard J.L., Bennet A.T. Physico-chemical characterization of a polymeric injectable implant system. J. Controlled Release. 33:1995;237-243.
60. Yewey G.L., Duysen E.G., Cox S.M., Dunn R.L. Delivery of proteins from a controlled release injectable implant. Sanders L.M., Hendren S. Protein Delivery: Physical Systems. 1997;93-117 Plenum, New York.
61. Lambert W.J., Peck K.D. Development of an in-situ forming biodegradable poly-lactide-co glycolide system for the controlled release of proteins. J. Controlled Release. 33:1995;189-195.
62. Chandrashekhar G., Udupa N. Biodegradable injectable implant system for long-term drug delivery using poly(lactide-co-glycolide) acid polymers. J. Pharm. Pharmacol. 48:1996;669-674.
63. Brodbeck J., DesNoyer J.R., McHugh A.J. Phase inversion dynamics of PLGA solutions related to drug delivery, Part II. The role of solution thermodynamics and bath-side mass transfer. J. Controlled Release. 62:1999;333-344.
64. R.L. Dunn, J.P. English, D.R. Cowsar, D.P. Vanderbilt, Biodegradable in situ forming implants and methods of producing the same, US patent No. 5,278,202, January 11, 1994.
65. R.L. Dunn, A.J. Tipton, J.A. Rogers, Biodegradable polymer composition, US patent No. 5,324,519, June 28, 1994.
66. R.L. Dunn, A.J. Tipton, Polymeric compositions useful as controlled release implants, US patent No. 5,702,716, December 30, 1997.
67. G.L. Yewey, N.L. Krinick, R.L. Dunn, M.L. Radomsky, G. Brouwer, A.J. Tipton, Liquid delivery compositions, US patent No. 5,780,044, July 14, 1998.
68. B.L. Chandrahskar, M. Zhou, E.M. Jarr, R.L. Dunn, Controlled Release Liquid Delivery Compositions with Low Initial Burst, WO publication No. 0024374, May 4, 2000.
69. K.V. Brodbeck, A.T. Gaynor-Duarte, T. Tao-Ian Shen, Gel compositions and methods, US patent No. 6,130,200, October 10, 2000.
70. R. Eliaz, J. Kost, Composition and method for forming biodegradable implants in situ and uses of these implants, WO publication No. 9742987, November 20, 1997.
71. Ravivarapu H.B., Moyer K.L., Dunn R.L. Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate. J. Pharm. Sci. 89:(6):2000;732-740.
72. Volland C., Wolff M., Kissel T. The influence of terminal gamma-irradiation on captopril containing poly(D,L-lactide-co-glycolide) microspheres. J. Controlled Release. 31:1994;293-305.
73. Mohr D., Wolff M., Kissel T. Gamma-irradiation for terminal sterilization of 17β-estradiol loaded poly(D,L-lactide-co-glycolide) microparticles. J. Controlled Release. 61:1999;203-217.
74. Nugroho P., Mitomo H., Yoshii F., Kume T. Degradation of poly(L-lactic acid) by gamma-irradiation. Polymer Degradation Stability. 72:(2):2001;334-337.
75. Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 21:2000;2475-2490.
76. Jain R.A., Rhodes C.T., Railkar A.M., Malick A.W., Shah N.H. Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: effect of various formulation variables. Eur. J. Pharm. Biopharm. 50:2000;257-262.
77. Jain R.A., Rhodes C.T., Railkar A.M., Malick A.W., Shah N.H. Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system. J. Microencapsul. 17:(3):2000;343-362.
78. Smith D.A., Tipton A.J. A novel parenteral delivery system. Pharm. Res. 19:(9):1996;300.
79. Darling S., Okumu F.W., Sullivan S.A., Tipton A.J., Clealand J.L. Extended release of human growth hormone suspended in Saber™ formulation design and in vitro assessment. Proc. Int. Symp. Control. Rel. Bioact. Mater. 28:2001;474-475.
80. Reynolds R.C., Chappel C.I. Sucrose acetate isobutyrate (SAIB): historical aspects of its use in beverages and a review of toxicity studies prior to 1988. Food Chem. Toxicol. 36:1998;81-93.
81. Reynolds R.C. Metabolism and pharmacokinetics of sucrose acetate isobutyrate (SAIB) and sucrose octoisobutyrate (SOIB) in rats, dogs, monkeys and humans: a review. Food Chem. Toxicol. 36:1998;95-99.
82. Procter B.G., Chappel C.I. Subchronic toxicity studies of sucrose acetate isobutyrate (SAIB) in the rat and dog. Food Chem. Toxicol. 36:1998;101-110.
83. Sullivan S.A., Gilley R.M., Gibson J.W., Tipton A.J. Delivery of Taxol™ and other antineoplastic agents from a novel system based on sucrose acetate isobutyrate. Pharm. Res. 14:(11):1997;291.
84. A. Sullivan, J.W. Gibson, P.J. Burns, L. Franz, E.L. Squires, D.L. Thompson, A.J. Tipton, Sustained release of progesterone and estradiol from Saber™ delivery system: in vitro and in vivo release rates, Southern Biosystems, Birmingham, AL, USA 35211, 1998.
85. Fleury J., Squires E.L., Betschart R., Gibson J., Sullivan S., Tipton A., Burns P.J. Evaluation of the Saber™ delivery system for the controlled release of deslorelin for advancing ovulation in the mare: effect of formulation and dose. Proc. Int. Symp. Control. Rel. Bioact. Mater. 25:1998;657-658.
86. Betschart R., Fleury J., Squires E.L., Nett T., Gibson J., Sullivan S., Tipton A., Burns P.J. Evaluation of the Saber™ delivery system for the controlled release of the GnRH analogue deslorelin for advancing ovulation in the mare: effect of gamma-irradiation. Proc. Int. Symp. Control. Rel. Bioact. Mater. 25:1998;655-656.
87. A.J. Tipton, R.J. Richard, High viscosity liquid controlled delivery system, US patent No. 5,747,058, May 5, 1998.
88. P.J. Burns, Composition for the controlled release of the hormone GnRH and its analogs, WO publication No. 0078335, December 28, 2000.
89. Burns P., Thompson D., Donadue F., Kincald L., Leise B., Gibson J., Swaim R., Tipton A.J. Pharmacodynamic evaluation of the Saber™ delivery system for the controlled release of the GnRH analogue deslorelin acetate for advancing ovulation in cyclic mares. Proc. Int. Symp. Control. Rel. Bioact. Mater. 24:1997;737-738.
90. J.Z. Krezanoski, Clear, water-miscible, liquid pharmaceutical vehicle which gels at body temperature for drug delivery to mucous membranes, US patent No. 4,188,373, February 12, 1980.
91. Wang P., Johnston T.P. Kinetic of sol-gel transition for poloxamer polyols. J. Appl. Polym. Sci. 43:1991;283-292.
92. Mortensen K., Pedersen J.S. Structural study on the micelle formation of poly(ethylene oxide)-polypropylene oxide)-poly(ethylene oxide) triblock copolymers in aqueous solution. Macromelecules. 26:1993;805-812.
93. Bhardwaj R., Blanchard J. Controlled-release delivery system for the α-MSH analog melanotan-I using Poloxamer 407. J. Pharm. Sci. 85:(9):1996;915-919.
94. Johnston T.P., Punjabi M., Froehlich C. Sustained delivery of interleukin-2 from a Poloxamer 407 gel matrix following intraperitoneal injection in mice. Pharm. Res. 9:(3):1992;425-434.
95. Fults K.A., Johnston T.P. Sustained release of urease from a Poloxamer gel matrix. J. Parenter. Sci. 44:(2):1990;58-65.
96. Veyries M.L., Couarraze G., Geiger S., Agnely F., Massias L., Kunzli B., Faurisson F., Rouveix B. Controlled release of vancomycin from Poloxamer 407 gels. Int. J. Pharm. 192:1999;183-193.
97. Johnston T.P., Miller S.C. Toxicological evaluations of Poloxamer vehicles for intramuscular use. J. Parenter. Sci. Technol. 39:(2):1985;83-88.
98. Blonder J.M., Baird L., Fulfs J.C., Rosenthal G.J. Dose-dependent hyperlipidemia in rabbits following administration of Poloxamer 407 gels. Life Sci. 65:(21):1999;261-266.
99. Engström S., Lindahl L., Wallin R., Engblom J. A study of polar lipid drug carrier systems undergoing a thermoreversible lamellar-to-cubic phase transition. Int. J. Pharm. 86:1992;137-145.
100. Engström S. Drug delivery from cubic and other lipid-water phases. Lipid Technol. 2:1990;42-45.
101. He R., Craig D.Q.M. Identification of thermotropic phase transitions of glyceryl monoolein/water systems by low frequency dielectric spectroscopy. Int. J. Pharm. 169:(2):1998;131-141.
102. Lindblom G., Rilfors L. Cubic phases and isotropic structures formed by membrane lipids - possible biological relevance. Biochem. Biophys. Acta. 98:1989;221-256.
103. S. Engström, K. Larsson, B. Lindman, Liquid cristalline phases as delivery systems for drugs I. Basic principles, Proc. Int. Symp. Control. Rel. Bioact. Mater. 15 (1988).
104. Ericsson B., Eriksson P.O., Löfroth J.E., Engström S. Cubic phases as delivery systems for peptide drugs. Dunn R.L., Ottenbrite R.M. Polymeric Drug and Drug Delivery. 1991;251-265 American Chemical Society, Washington DC, USA. Chapter 22.
105. Wyatt D.M., Dorschel D. A cubic-phase delivery system composed of glyceryl monooleat and water for sustained release of water-soluble drugs. Pharm. Technol. 10:1992;116-130.
106. He R., Craig D.Q.M. Glyceryl monoolein/water gel systems using low frequency dielectric spectroscopy. J. Pharm. Sci. 88:(6):1999;634-639.
107. Engstrom S., Engstrom L. Phase behaviour of the lidocaine-monoolein-water system. Int. J. Pharm. 79:1992;113-122.
108. Cramp F.C., Lucy J.A. Glyceryl monooleate as a fusogen for the formation of heterokaryons and interspecific hybrid cells. Exp. Cell Res. 87:1974;107-110.
109. Hope M.J., Cullis P.R. The role of non-bilayer lipid structure in the fusion of human erythrocytes induced by lipid fusogens. Biochem. Biophys. Acta. 640:(1):1981;82-90.
110. S. Engstrom, B. Lindman, K. Larson, Method of preparing controlled release preparations for biologically active materials and resulting compositions, WO publication No. 8402076, June 11, 1984.
111. S. Engstrom, B. Lindman, K. Larson, A controlled-release composition for a biologically active material dissolved or dispersed in an L2-phase, WO publication No. 8800059, January 14, 1988.
112. S. Engstrom, B. Lindman, K. Larson, Method of preparing controlled release preparations for biologically active materials and resulting compositions, US patent No. 5,151,272, September 29, 1992.
113. L. Landh, K. Larson, Particles, method of preparing said particles and uses thereof, US patent No. 5,531,925, July 2, 1996.
114. H. Ljusberg-Wahren, K. Larson, Lipid based composition containing diacylglycerol, phospholipid, polar liquid and biologically active material, WO publication No. 9534287, December 21, 1995.
115. Bae Y.H., Kim S.W. Hydrogel delivery systems based on polymer blends, block co-polymers or interpenetrating networks. Adv. Drug Deliv. Rev. 11:1993;109-135.
116. Youxin L., Kissel T. Synthesis and properties of biodegradable ABA triblock copolymers consisting of poly(L-lactic) acid or poly(L-lactic-co-glycolic) acid A-blocks attached to central poly(oxyethylene) B-blocks. J. Controlled Release. 27:1993;247-257.
117. Jeong B., Bae Y.H., Kim S.W. Biodegradable block copolymers as injectable drug-delivery systems. Nature. 388:1997;860-862.
118. Jeong B., Bae Y.H., Kim S.W. Biodegradable thermosensitive micelles of PEG-PLGA-PEG triblock copolymers. Colloids Surfaces B: Biosurfaces. 16:1999;185-193.
119. Jeong B., Bae Y.H., Kim S.W. Thermoreversible gelation of PEG-PLGA-PEG triblock copolymers aqueous solutions. Macromolecules. 32:(21):1999;7064-7069.
120. Jeong B., Choi Y.K., Bae Y.H., Zentner G., Kim S.W. New biodegradable polymers for injectable drug delivery systems. J. Controlled Release. 62:1999;109-114.
121. Jeong B., Bae Y.H., Kim S.W. Drug release from biodegradable injectable thermosensitive hydrogel of PEG-PLGA-PEG triblock copolymers. J. Controlled Release. 63:2000;155-163.
122. Jeong B., Bae Y.H., Kim S.W. In situ gelation of PEG-PLGA-PEG triblock copolymer aqueous solution and degradation thereof. J. Biomed. Mater. Res. 50:(2):2000;171-177.
123. Y. Cha, Y.K. Choi, Y.H. Bae, Thermosensitive biodegradable polymers based on poly(ether-ester) block copolymers, US patent No. 5,702717, December 30, 1997.
124. B. Jeong, Y.H. Bae, S.W. Kim, Injectable biodegradable block copolymer gels for use in drug delivery, WO publication No. 9907343, February 18, 1999.
125. R. Rathi, G.M. Zentner, B. Jeong, Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethyleneglycol copolymers having reverse thermal gelation properties, WO publication No. 0018821, April 6, 2000.
126. Hagelund B.A., Joshi R., Himmelstein K.J. An in situ gelling system for parenteral delivery. J. Controlled Release. 41:1996;229-235.
127. Joshi R., Arora V., Desjardin J.P., Robinson D., Himmelstein K.J., Iversen P.L. In vivo properties of an in situ forming gel for parenteral delivery of macromolecular drugs. Pharm. Res. 15:(8):1998;1189-1195.
128. K.J. Himmelstein, In situ gel-forming delivery vehicle for bio-affecting substances and method of use, WO publication No. 9535093, December 28, 1995.
129. A. Joshi, S. Ding, K.J. Himmelstein, Reversible gelation composition and method of use, WO publication No. 9119481, December 26, 1991.
130. A. Joshi, S. Ding, K.J. Himmelstein, Reversible gelation composition and method of use, US patent No. 5,252,318, October 12, 1993.
131. A.L. Hoeg, D.L. Meadows, Reversible gelation emulsion composition and method of use, US patent No. 5,441,9732, August 15, 1995.